title: The somatostatin analog octreotide as potential treatment for re-stenosis and chronic rejection.
authors.affiliation: Transplantation and Core Technology Department, Novartis Pharma Research, Basel, Switzerland.
authors.forename: G
authors.initials: G
authors.lastname: Weckbecker
authors.forename: C
authors.initials: C
authors.lastname: Pally
authors.forename: F
authors.initials: F
authors.lastname: Raulf
authors.forename: N
authors.initials: N
authors.lastname: Beckmann
authors.forename: J H
authors.initials: JH
authors.lastname: Schuurman
authors.forename: M
authors.initials: M
authors.lastname: Rudin
authors.forename: C
authors.initials: C
authors.lastname: Bruns
mesh_terms: D017130:Angioplasty / Q000009:adverse effects; D000818:Animals; D001807:Blood Vessel Prosthesis / Q000009:adverse effects; D002339:Carotid Arteries / Q000473:pathology; D002455:Cell Division / Q000187:drug effects; D002465:Cell Movement / Q000187:drug effects; D006083:Graft Occlusion, Vascular / Q000517:prevention & control*; D006728:Hormones / Q000008:administration & dosage*; D015282:Octreotide / Q000008:administration & dosage*; D051381:Rats; D017540:Tunica Media / Q000187:drug effects / Q000473:pathology*; D014652:Vascular Diseases / Q000188:drug therapy* / Q000473:pathology
chemical_list: D006728:Hormones; D015282:Octreotide